Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Accuitis

Accuitis
2011 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE
$1.75M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer and marketer of pharmaceuticals for dermatological diseases. The company provides drugs for the treatment of rosacea, which is a dermatological ophthalmic condition.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 4920 Pond Ridge Lane
  • Cumming, GA 30041
  • United States

+1 (678) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Accuitis’s full profile, request a free trial.

Accuitis Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 05-Sep-2017 $1.75M 00.000 Completed Startup
1. Grant Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Accuitis Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bio/Med Investor Network Angel Group Minority 000 0000 000000 0
Georgia Research Alliance Government 000 0000 000000 0
Robert Thomas Angel (individual) Minority 000 0000 000000 0
GRA Venture Fund Venture Capital Minority 000 0000 000000 0

Accuitis Executive Team (4)

Name Title Board
Seat
Contact
Info
Richard Coulon Chief Executive Officer, Co-Founder and President
Michael Shippel Chief Financial Officer & Board Member
Mark Jackson MD Medical Consultant
Jack Arbiser Ph.D Co-Founder & Chief Innovation Officer

Accuitis Board Members (5)

Name Representing Role Since Contact
Info
Geoffrey Meacham Bio/Med Investor Network Board Member 000 0000
Michael Shippel Accuitis Chief Financial Officer & Board Member 000 0000
Robert Thomas Ph.D Self Board Member 000 0000
Stephen Martin JD Self Board Member 000 0000

1 Former Board Member

You’re viewing 4 of 5 board members. Get the full list »